James B. Ford
No Rating Available
(Learn About Our Rating System)

James B. Ford, DO

Languages spoken: Spanish, English, Portuguese

Clinical Locations

Primary Location

Primary Children's Hospital

Pediatric Hematology/Oncology
100 N Mario Capecchi Drive
Salt Lake City , UT 84113
Get Directions

Dr. Ford is currently an associate professor at the University of Utah School of Medicine in the division of Pediatric Hematology/Oncology. He is a member of the Leukemia and Lymphoma Team at the University of Utah and Primary Children’s Hospital. He received his medical degree from Des Moines University College of Osteopathic Medicine.

Dr. Ford completed his residency at Akron Children’s Hospital specializing in Pediatrics. He pursued his Hematology, Oncology and Bone Marrow Transplantation Fellowship at the University of Colorado School of Medicine, Children’s Hospital Colorado.

Dr. Ford is board-certified in Pediatrics and Pediatric Hematology and Oncology. He has authored several articles in peer-reviewed journals and has been the principal investigator in several grants.

Dr. Ford’s clinical interests include the treatment of pediatric Leukemia and Lymphoma. He has an emphasis in post-transplant lymphoproliferative disorder and Non-Hodgkin Lymphomas.

His primary research focuses on Non-Hodgkin Lymphoma. He is involved in clinical trials for relapsed T-cell lymphoblastic lymphoma and relapsed mature B cell lymphoma. He is also interested in discovering risk factors leading to relapse in T-cell lymphoblastic lymphoma.

Specialties

Board Certification

American Board of Pediatrics (Pediatrics)
American Board of Pediatrics (Sub: Pediatric Hematology-Oncology)

Dr. Ford is currently an associate professor at the University of Utah School of Medicine in the division of Pediatric Hematology/Oncology. He is a member of the Leukemia and Lymphoma Team at the University of Utah and Primary Children’s Hospital. He received his medical degree from Des Moines University College of Osteopathic Medicine.

Dr. Ford completed his residency at Akron Children’s Hospital specializing in Pediatrics. He pursued his Hematology, Oncology and Bone Marrow Transplantation Fellowship at the University of Colorado School of Medicine, Children’s Hospital Colorado.

Dr. Ford is board-certified in Pediatrics and Pediatric Hematology and Oncology. He has authored several articles in peer-reviewed journals and has been the principal investigator in several grants.

Dr. Ford’s clinical interests include the treatment of pediatric Leukemia and Lymphoma. He has an emphasis in post-transplant lymphoproliferative disorder and Non-Hodgkin Lymphomas.

His primary research focuses on Non-Hodgkin Lymphoma. He is involved in clinical trials for relapsed T-cell lymphoblastic lymphoma and relapsed mature B cell lymphoma. He is also interested in discovering risk factors leading to relapse in T-cell lymphoblastic lymphoma.

Board Certification and Academic Information

Academic Departments Pediatrics -Associate Professor (Clinical)
Academic Divisions Hematology/Oncology
Board Certification
American Board of Pediatrics (Pediatrics)
American Board of Pediatrics (Sub: Pediatric Hematology-Oncology)

Education history

Undergraduate Double Major: Biology and Behavioral Science & Health - University of Utah B.S.
Professional Medical Osteopathic Medicine - Des Moines University College of Osteopathic Medicine D.O.
Residency Pediatrics - Northeast Ohio Medical University, Akron Children's Hospital Resident
Fellowship Hematology, Oncology and Bone Marrow Transplantation - University of Colorado School of Medicine, Children¿s Hospital Colorado Fellow

Selected Publications

Journal Article

  1. Davies K, Barth M, Armenian S, Audino AN, Barnette P, Cuglievan B, Ding H, Ford JB, Galardy PJ, Gardner R, Hanna R, Hayashi R, Kovach AE, Machnitz AJ, Maloney KW, Marks L, Page K, Reilly AF, Weinstein JL, Xavier AC, McMillian NR, Freedman-Cass D (2020). Pediatric Aggressive Mature B-Cell Lymphomas, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network, 18(8), 1105-1123.
  2. Allison J*, Drury L, Ford J (2020). Two Novel TMPRSS6 Variants in a Compound Heterozygous Child With Iron Refractory Iron Deficiency Anemia. Journal of pediatric hematology/oncology, 42(4), e238-e239.
  3. Wolf A*, Rohr JM*, Amador C, Starr LJ, Hoyer JD, Ford J (2019). Hb Gibbon [β124(H2)Pro→Thr (HBB: c.373C>A, p.P125T)], an Asymptomatic Novel Hemoglobin Variant Detected by Newborn Screening. Hemoglobin, 43(3), 207-209.
  4. Ford JB, Baturin D, Burleson TM, Van Linden AA, Kim YM, Porter C (2015). AZD1775 sensitizes T cell acute lymphoblastic leukemia cells to cytarabine by promoting apoptosis over DNA repair. Oncotarget, 6(29), 28001-10.
  5. Van Linden AA, Baturin D, Ford JB, Fosmire SP, Gardner L, Korch C, Reigan P, Porter C (2013). Inhibition of Wee1 sensitizes cancer cells to antimetabolite chemotherapeutics in vitro and in vivo, independent of p53 functionality. Molecular cancer therapeutics, 12(12), 2675-84.
  6. Cave C*, Ramirez R, High R, Ford J, Raulji C, Beck (2023). Vincristine Side Effects With Concomitant Fluconazole Use During Induction Chemotherapy in Pediatric Acute Lymphoblastic Leukemia. Journal of pediatric hematology/oncology, 45(7), e861-e866.
  7. Afify ZAM, Taj MM, Orjuela-Grimm M, Srivatsa K, Miller TP, Edington HJ, Dalal M, Robles J, Ford JB, Ehrhardt MJ, Ureda TJ, Rubinstein JD, McCormack S, Rivers JM, Chisholm KM, Kavanaugh MK, Bukowinski AJ, Friehling ED, Ford MC, Reddy SN, Marks LJ, Smith CM, Mason C (2023). Multicenter study of pediatric Epstein-Barr virus-negative monomorphic post solid organ transplant lymphoproliferative disorders. Cancer, 129(5), 780-789.
  8. Haney SL, Feng D, Chhonker YS, Varney ML, Williams JT, Smith LM, Ford JB, Murry DJ, Holstein S (2023). Evaluation of geranylgeranyl diphosphate synthase inhibition as a novel strategy for the treatment of osteosarcoma and Ewing sarcoma. Drug development research, 84(1), 62-74.
  9. Afify Z, Orjuela-Grimm M, Smith CM, Dalal M, Ford JB, Pillai P, Robles JM, Reddy S, McCormack S, Ehrhardt MJ, Ureda T, Alperstein W, Edington H, Miller TP, Rubinstein JD, Kavanaugh M, Bukowinski AJ, Friehling E, Rivers JM, Chisholm KM, Marks LJ, Mason C (2023). Burkitt lymphoma after solid-organ transplant: Treatment and outcomes in the paediatric PTLD collaborative. British journal of haematology, 200(3), 297-305.
  10. Cochran T*, Patel S, Kruse T, Lyden E, Comer S*, Ford (2023). Sensitivity and Specificity of Whole-body MRI for the Detection of Pediatric Malignancy. Journal of pediatric hematology/oncology, 45(1), e26-e30.
  11. Barth M, Xavier AC, Armenian S, Audino AN, Blazin L, Bloom D, Chung J, Davies K, Ding H, Ford JB, Galardy PJ, Hanna R, Hayashi R, Lee-Miller C, Machnitz AJ, Maloney KW, Marks L, Martin PL, McCall D, Pacheco M, Reilly AF, Roshal M, Song S, Weinstein J, Zarnegar-Lumley S, McMillian N, Schonfeld R, Sundar (2022). Pediatric Aggressive Mature B-Cell Lymphomas, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network, 20(11), 1267-1275.
  12. Slatnick LR, Thornhill D, Deakyne Davies SJ, Ford JB, Scott HF, Manco-Johnson MJ, Warren B (2020). Disseminated Intravascular Coagulation Is an Independent Predictor of Adverse Outcomes in Children in the Emergency Department with Suspected Sepsis. The Journal of pediatrics, 225, 198-206.e2.
  13. Si Lim SJ, Ford JB, Hermiston M (2023). How I treat newly diagnosed and refractory T-cell acute lymphoblastic lymphoma in children and young adults. Blood, 141(25), 3019-3030.
  14. Haney SL, Feng D, Kollala SS, Chhonker YS, Varney ML, Williams JT, Ford JB, Murry DJ, Holstein S (2024). Investigation of the activity of a novel tropolone in osteosarcoma. Drug development research, 85(1), e22129.

Case Report

  1. Hagelstrom RT, Ford J, Reiser GM, Nelson M, Pickering DL, Althof PA, Sanger WG, Coccia P (2016). Breast Cancer and Non-Hodgkin Lymphoma in a Young Male with Cowden Syndrome. Pediatric blood & cancer, 63(3), 544-6.
  2. Kwan KR*, Skokan S, Blesh-Boren T, Vogel J, Harter N, Ford J (2024). Chemotherapeutic metabolism presenting as a recalcitrant case of hand-foot syndrome and mucositis. Journal of oncology pharmacy practice, 30(3), 584-588.

Letter

  1. Zhou DJ*, Darwish M, Ford JB, Patel S, Koh S, Rathore GS, Zabad R (2023). Pediatric CLIPPERS? Think again!. Journal of the neurological sciences, 451, 120698.

Abstract

  1. Kristin A. Shimano, MD, Amanda B. Grimes, MD, Melissa J Rose, DO, Shipra Kaicker, MD, Sanjay J. Shah, MBBS, Michael Briones, DO, Elizabeth Gunn, MD, Taizo A. Nakano, MD, Jeffrey D Lebensburger, DO, Michele P. Lambert, MD, Stephanie A. Fritch Lilla, MD, Rohith Jesudas, MBBS, Cathy A. Lee-Miller, MD, Alexis Thompson, MD, MPH, Rukhmi Bhat, MD, MS, Stacey Rifkin-Zenenberg, DO, Suvankar Majumdar, MBBChir, Manpreet Kochhar, MD, MS, Shelley E Crary,MD, MS, Kerry Hege, MD, Jennifer A. Rothman, MD, James B. Ford, DO, Joshua J Bies, MD, John Fort, MD, Loan Hsieh, MD, Maritza E. Ruiz, MD, Kathryn M. Carrier, Bogdan Dinu, Julia MW Wong, PhD, RD, Pei-Chi Kao, Wendy B. London, PhD, Staci D. Arnold, MD, MBA, MPH, Carolyn M. Bennett, MD, MSc, Jenny Despotovic, DO, Robert J. Klaassen, MD, FRCPC, Ellis J. Neufeld, MD, Cindy E Neunert, MD and Rachael F. Grace, MD, MMS (2024). Efficacy Findings in a Phase 3, Randomized Trial of Eltrombopag Vs. Standard First-Line Treatment for Newly Diagnosed Immune Thrombocytopenia in Children. 144(Supplement 1), 709.